Data on cholesterol drug fenofibrate lead to FDA advisory

11/9/2011 | Medscape (free registration)

Data from the ACCORD Lipid trial showed the cholesterol-lowering drug fenofibric acid or fenofibrate may not reduce the risk of major cardiovascular events, leading the FDA to issue a safety communication and update prescribing information. The agency also asked for a trial to study the medication's cardiovascular effects in patients on statins.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ